Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Actelion Pharmaceuticals Ltd (SWF:ATLN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
ALLSCHWIL/Basel, SWITZERLAND - 22 September 2008 - Actelion Ltd (SWX: ATLN) announced that, as of today, Monday 22 September 2008, its shares (ATLN, CH001053247) will start trading as part of the Swiss Market Index SMI®, the Swiss blue-chip index.
Jean-Paul Clozel, M.D. and Chief Executive Officer commented: "In just eight years following Actelion's initial listing on the Swiss Stock Exchange, our ability to create growth and subsequent long-term shareholder value has been recognized by today's inclusion of our shares in the SMI®. We are proud to be part of a stock market index, which includes some of the best companies in the world. For Actelion, this inclusion is a milestone in our short history and an inspiration to continue the discovery, development and marketing of innovative medicines that have the potential to change patients' lives."
As a blue-chip index, the SMI® is Switzerland's key equity index. It represents about 85% of the free-float capitalization of the Swiss equity market. The index comprises the 20 largest and most liquid equities of the SPI® (Swiss Performance Index®). Since the SMI® is considered to be a mirror of the overall Swiss stock market, it is used as the underlying index for numerous derivative financial instruments such as options, futures and index funds (e.g. ETFs). The composition of the index is examined - and - if appropriate - updated once a year. More details about the SMI® index are available on the SWX Swiss Exchange website at www.swx.com
###
Actelion Ltd Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 1700 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI® )
For further information please contact: Roland Haefeli Vice President, Head of Investor Relations & Public Affairs Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 +1 650 624 69 36 http://www.actelion.com
Upcoming Corporate Events
+-------------------------------------------------------------------+ | Tuesday 21 October, 2008 | 9-months 2008 results: | | | -Update on development pipeline | | | (webcast only) | | | | |--------------------------+----------------------------------------| | Thursday February 19, | Actelion Day, Allschwil / Switzerland: | | 2009 | -Full Year 2008 results | | | -Research & Development presentations | | | -Tour of Actelion's Research | | | facilities | +-------------------------------------------------------------------+
The Sleep 101 educational event has been moved to 2009.
